Waud Capital Partners, a growth-oriented middle market private equity firm based in Chicago, announced on September 14 that it launched PharmAlliance Holdings, LLC. This was done in partnership with Mark Bouck, who will serve as Chief Executive Officer of the platform.
PharmAlliance Holdings is a diversified pharmaceutical and life sciences services provider focused on discovery, development and commercialization solutions. Its services span across the drug life cycle for pharmaceutical, biotechnology, life sciences and medical device companies.
In conjunction with its launch, PharmAlliance invested in BioBridges, a drug development consulting business serving pharmaceutical sponsors and biotechnology companies. Prior to PharmAlliance’s investment, the company was a wholly-owned subsidiary of Soliant Health, a portfolio company of private equity firm Olympus Partners.
Mr. Bouck commented, “We believe BioBridges is an exceptional entry point from which to create a sector-leading business in the large, growing and fragmented pharma services market. I could not be more pleased with the outcome and the support received from Waud Capital throughout this process.”
According to data captured in the LevinPro HC database, this is Waud Capital’s 12th transaction of 2023. Previously, it acquired four gastroenterology practices, three eye care practices, three rehabilitation facilities and one ambulatory surgery center.
